Curis (CRIS) EGM 2026 summary
Event summary combining transcript, slides, and related documents.
EGM 2026 summary
25 Jun, 2026Opening remarks and agenda
The meeting was called to order by the CEO, who welcomed stockholders and outlined the agenda and rules of conduct for the virtual special meeting.
The meeting was recorded, and validated stockholders were invited to submit questions about the proposals.
Legal counsel and all directors participated telephonically.
Specific resolutions to be voted on
Proposal to amend the certificate of incorporation to effect a reverse stock split at a ratio between 1-for-5 and 1-for-25, at the board's discretion.
Proposal to adjourn the meeting to a later date if necessary to solicit more proxies for the reverse stock split.
Corporate governance
Inspector of Election from Broadridge Financial Solutions was appointed to oversee voting and quorum.
Quorum was established with 27,773,949 shares represented out of 38,978,693 outstanding.
Latest events from Curis
- Emavusertib shows superior efficacy and safety in lymphoma and AML, with broad expansion plans.CRIS
Corporate presentation5 Jun 2026 - Shareholders will vote on a reverse stock split to help maintain Nasdaq listing compliance.CRIS
Proxy filing5 Jun 2026 - Shareholders to vote on a reverse stock split to help maintain Nasdaq listing compliance.CRIS
Proxy filing22 May 2026 - All five shareholder proposals, including director elections and share increase, were approved.CRIS
AGM 202619 May 2026 - Q1 2026 net loss was $24.2M; cash runway extends into H2 2027, but viability is uncertain.CRIS
Q1 202613 May 2026 - Shareholders will vote on director elections, executive pay, auditor ratification, and a share increase.CRIS
Proxy filing22 Apr 2026 - Shareholders will vote on director elections, executive pay, auditor ratification, and a major share increase.CRIS
Proxy filing10 Apr 2026 - Emavusertib delivers deep, durable responses in blood cancers and advances toward registrational trials.CRIS
Corporate presentation1 Apr 2026 - Q4 2025 net income surged on Erivedge sale; PCNSL and CLL studies drive future growth.CRIS
Q4 202520 Mar 2026